Sign in
Active, not recruitingPhase 1

Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Phase 1
People taking part
4 people enrolled
Started
26 Mar 2026
Expected to end
Feb 2027
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Semaglutide 1.0 mg
Record updated
10 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study (up to 6 months: 3-month treatment plus 3-month follow up)
  • Age 18 and older
  • Have a BMI ≥30 (or BMI ≥27 with a medical comorbidity) and BMI ≤50 kg/m2
  • Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy within the past seven years
  • Meet current DSM-5 criteria for Alcohol Use Disorder
  • Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators
  • Read, comprehend, and write English at a sufficient level to complete study-related materials
  • For females of reproductive potential: use of highly effective contraception and agreement to use such a method during study participation

Who cannot take part

  • Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening
  • Is currently using other medications for weight loss or other GLP-1 receptor agonists
  • Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device
  • History of malignant neoplasms within the past 5 years prior to screening
  • Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2
  • Has a history of allergy or sensitivity to Semaglutide
  • Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)
  • Has untreated hypertension with a seated systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg, or heart rate > 100 beats/minute
  • Has current uncontrolled hypertension
  • Has current uncontrolled Type I or Type II diabetes mellitus
  • Has active gallbladder disease
  • Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder
  • Has a recent history of substance use disorder (with the exception of cannabis or tobacco use disorder) within the past 12 months
  • Is currently engaging in other treatment for Alcohol Use Disorder or making intentional efforts to quit alcohol use
  • Any disorder, unwillingness or inability, not covered by any of the other exclusion criteria which, in the investigator's opinion, might have jeopardized the participant's safety or compliance with the protocol
  • Has untreated hypothyroidism with a TSH > 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit
  • History or presence of chronic or recurrent pancreatitis
  • Is breast-feeding, pregnant, or not using a reliable form of birth control
  • Reports active suicidal or homicidal ideation

Where in United States

  • Yale School of MedicineNew Haven, United States

About the trial

What the trial wants to find out

The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.

The 2 groups in the trial

  • SemaglutideTreatment being tested

    Participants randomized to Semaglutide will be initiated on a 0.25 mg dose (injection) once weekly for 4 weeks (first month) with an escalation to 0.5 mg for the second month, and 1.0 mg in the final month. Participants will be on Semaglutide for three months total.

    Treatment: Semaglutide 1.0 mg

  • Wait-list controlNo study treatment, for comparison

    Participants randomized to wait-list control will be followed for three months but no treatment will be administered. At the conclusion of the study, participants in the wait list control group will be offered a three-month behavioral intervention to treat Alcohol Use Disorder, although this is not required.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Semaglutide Treatment for Alcohol Use Disorder After Metabolic and Bariatric Surgery: A Pilot Randomized Controlled Trial
Record updated
10 September 2026